Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer. - Wikidata - wikimedia - TriplyDB

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

http://www.wikidata.org/entity/Q33407805

about

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer Paclitaxel, Carboplatin, and trastuzumab.Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo.Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab.Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?

P2860

Q33712925-3FE8F676-8F20-4EE6-92CF-67476306B510 Q33730822-C988ABC5-72D7-4D6E-9AF7-AA85AEB1C99C Q34612916-351C4768-C94B-4F0C-A151-119B804BFE7F Q35185733-60F0B677-1C63-4B30-ADB6-2496805DC101 Q36629452-7500A9E4-CF6F-4087-A8DF-098B6BDB5C50 Q39015610-2EA832D2-4B8B-4A61-8145-23FA26B0EE69 Q41345524-BB2E2DD0-5C45-45AE-BE80-12598472CA5D Q47822633-5D057E83-3EEC-486B-A898-CC11C454A05D Q54242357-66A4A31C-F11D-4961-BA9B-A775849B609F

P2860

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

http://www.wikidata.org/entity/Q33407805

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Paclitaxel, carboplatin, and t ...... r HER2-positive breast cancer.

@ast

Paclitaxel, carboplatin, and t ...... r HER2-positive breast cancer.

@en

type

label

Paclitaxel, carboplatin, and t ...... r HER2-positive breast cancer.

@ast

Paclitaxel, carboplatin, and t ...... r HER2-positive breast cancer.

@en

prefLabel

Paclitaxel, carboplatin, and t ...... r HER2-positive breast cancer.

@ast

Paclitaxel, carboplatin, and t ...... r HER2-positive breast cancer.

@en

P1433

Q33407805-ED50CAA0-066C-491A-9A19-D265DD6BD7D9

P1476

Q33407805-28F675F6-D8DD-42C5-B6F5-A52E01F69812

P2093

Q33407805-0114E0CD-6E1F-4C97-B93E-880006A014DB

Q33407805-16E20D9F-BFC7-4D92-8ED5-5151F73FF308

Q33407805-6A3C909D-2796-4841-858D-7495A03A3235

Q33407805-6CC3CE5A-B243-4E1E-8FC0-701A87084DDD

Q33407805-B744A7AA-DB7C-4E8C-AC9D-FA19A143E176

Q33407805-BA3B8E18-62AA-4B41-96D0-409E74C30E4B

Q33407805-BC9CF055-4315-433D-B6C7-FB40E2578600

Q33407805-DEF580A7-9D4E-4760-AFD4-60569690B8BA

P2860

Q33407805-00F906DF-3F32-4BDC-AA2E-FE189D0F7AFF

Q33407805-05E2546A-2D5E-4C42-A928-545A222F164F

Q33407805-0E89AA59-AAE2-40C2-819B-46244BD4AA3C

Q33407805-0F3F637F-4B96-4ED7-8110-1A2F79B92463

Q33407805-2365261B-4366-4F18-A616-6C48B49F0114

Q33407805-40D2B1F9-3174-4A1E-9C0A-F900A6F7F992

Q33407805-45362D4B-B753-4283-A3D7-69D1DE99861D

Q33407805-46532225-ED3C-47C2-8D25-36F794BBEE83

Q33407805-4815C99C-6354-43FF-8C29-CB2F4364D250

Q33407805-54955E3D-9CA7-4416-A6AD-B6D758A7281D

P304

Q33407805-8A89922A-7D18-4735-83EE-27F216811ECA

P31

Q33407805-7F561012-C6AF-433D-A792-EF88CE9CF020

P356

Q33407805-D4B09DD3-96B3-4263-B270-770378AD6F5D

P433

Q33407805-1C260DB7-DE09-438F-B418-C50BC75753E7

P478

Q33407805-5403EC52-95DB-499A-BBE5-C2B107024245

P50

Q33407805-BBD53062-0417-4A54-AA07-298B2E66E271

P577

Q33407805-2E3D7A86-8A61-4A4A-9E64-4613A3BBCC32

P698

Q33407805-7C980C2F-91E8-4ECF-BF17-4CD1C2E353C2

P356

P1433

The Breast Journal

P1476

Paclitaxel, carboplatin, and t ...... r HER2-positive breast cancer.

@en

P2093

Erik van Werkhoven

http://www.w3.org/2001/XMLSchema#string

Ingrid A Mandjes

http://www.w3.org/2001/XMLSchema#string

Jelle Wesseling

http://www.w3.org/2001/XMLSchema#string

Margaret Schot

http://www.w3.org/2001/XMLSchema#string

Marie-Jeanne Vrancken Peeters

http://www.w3.org/2001/XMLSchema#string

Marjo J Holtkamp

http://www.w3.org/2001/XMLSchema#string

Sabine C Linn

http://www.w3.org/2001/XMLSchema#string

Sjoerd Rodenhuis

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

P304

419-426

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TBJ.12124

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23682812

http://www.w3.org/2001/XMLSchema#string